ACM
BCAX

ADAR1 Capital Management’s Bicara Therapeutics BCAX Stock Holding History

ADAR1 Capital Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$407K Hold
13,705
– – 0.02% 224
2026
Q1 		$273K Hold
13,705
– – 0.02% 246
2025
Q4 		$231K Hold
13,705
– – 0.02% 226
2025
Q3 		$216K Sell
13,705
-9,170
-40% -$103K 0.02% 178
2025
Q2 		$213K Buy
+22,875
New +$273K 0.03% 154
2024
Q4 		– Sell
-40,440
Closed -$1.03M – 316
2024
Q3 		$1.03M Buy
+40,440
New +$1.03M 0.17% 75

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ADAR1 Capital Management's BCAX Position: Q2 2026 in Review

ADAR1 Capital Management held its Bicara Therapeutics (BCAX) position steady in Q2 2026 at 13,705 shares worth $407K. The position accounts for 0.02% of the portfolio, ranked #224.

ADAR1 Capital Management first reported a position in BCAX in Q3 2024 and has held it in 6 quarters since. The position peaked at $1.03M in Q3 2024. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • ADAR1 Capital Management held 13,705 shares of Bicara Therapeutics worth $407K as of Q2 2026.
  • ADAR1 Capital Management left its Bicara Therapeutics share count unchanged in Q2 2026.
  • Bicara Therapeutics made up 0.02% of ADAR1 Capital Management's portfolio in Q2 2026, its #224 holding.
  • ADAR1 Capital Management first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • ADAR1 Capital Management's Bicara Therapeutics position peaked at $1.03M in Q3 2024.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.